All In Biotech

Drug Trial Radar · NCT04733183

Efficacy and Safety of L19TNF in Previously Treated Patients with Advanced Stage or Metastatic Soft-tissue Sarcoma

A Randomized Study to Investigate the Efficacy and Safety of the Tumor-targeting Human Antibody-cytokine Fusion Protein L19TNF in Previously Treated Patients with Advanced Stage or Metastatic Soft-tissue Sarcoma

Last checked: Nov 19, 2026Latest source record: Jan 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

98

Planned (sponsor's estimate)

Start

Aug 28, 2020

Primary completion

Dec 2025

Study completion Dec 2025

Sponsor

Lead sponsor
Philogen S.p.A.Industry
Sponsor type
Industry
First posted
Feb 1, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Open label, randomized, controlled phase II study preceded by a safety run-in part in subjects with advanced or metastatic soft-tissue sarcoma.

Conditions

  • Soft Tissue Sarcoma

Interventions

  • DacarbazineDrug

    Dacarbazine (DTIC), 1000 mg/m2 or 850 mg/m2 on Day 1 of every 21-day cycle (based on results and DSMB evaluation in the safety run-in part of the study)

  • onfekafusp alfaDrug

    L19TNF, 13 μg/kg, on Day 1, 3, and 5 of every 21-day cycle for a maximum of 6 induction cycles. Patients experiencing apparent or real benefit with minimal or acceptable toxicity from the first 6 cycles of treatment, can receive, at investigator's discretion, maintenance treatment of 13 μg/kg, on Day 1 every 21-day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival (PFS)Time frame: The PFS rate will be assessed at 3 months.
  2. Progression-free survival (PFS)Time frame: The PFS rate will be assessed at 6 months.
  3. Progression-free survival (PFS)Time frame: The PFS rate will be assessed at 9 months.
  4. Progression-free survival (PFS)Time frame: The PFS rate will be assessed at 12 months.

Locations

23 sites in 5 countries. Site status is shown where the registry gives one.

  • Hopital Jean Minjoz

    Besançon, France

  • Institut Bergonié

    Bordeaux, France

  • Centre Jean Perrin

    Clermont-Ferrand, France

  • Centre Léon Bérard

    Lyon, France

  • Institut Paoli-Calmettes

    Marseille, France

  • Institut régional du Cancer de Montepellier - ICM Val d'Aurelle

    Montpellier, France

  • Institut Claudius Regaud

    Toulouse, France

  • Institut Gustave Roussy

    Villejuif, France

  • Helios Klinikum Bad Saarow

    Bad Saarow, Germany

  • Helios Klinikum Berlin- Buch

    Berlin, Germany

  • Klinik rechts der Isar, TU München

    München, Germany

  • Münster University Hospital

    Münster, Münster, Germany

  • IRCCS - Istituto Ortopedico Rizzoli

    Bologna, Italy

  • IRCCS Fondazione del Piemonte per l'Oncologia Istituto per la Ricerca e la Cura del Cancro di Candiolo

    Candiolo, Italy

  • AOU San Luigi Gonzaga

    Orbassano, Italy

  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS

    Roma, Italy

  • Szpital Pomorski Im. PCK

    Gdynia, Poland

  • Maria Sklodowska Curie National Research Institute of Oncology

    Warsaw, Poland

  • Hospital Universitario Fundación Jiménez Díaz

    Madrid, Spain

  • Hospital Universitario Virgen de La Victoria

    Málaga, Spain

  • Hospital Universitario de Canarias

    San Cristóbal de La Laguna, Spain

  • Hospital Universitario Donostia

    San Sebastián, Spain

  • Hospital Clínico Universitario de Valencia

    Valencia, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.